The company said total revenue for Q3 2026 rose 11% year over year to $2.8 billion, and Growth Portfolio revenue rose 49% to $1.26 billion. It said the results included the first full quarter contribution from Apellis products.

1. 01

   The company said total revenue for Q3 2026 rose 11% year over year to $2.8 billion, and Growth Portfolio revenue rose 49% to $1.26 billion. It said the results included the first full quarter contribution from Apellis products.

2. 02

   Biogen said GAAP diluted EPS for Q3 2026 was $(0.14), and Non-GAAP diluted EPS was $2.62. Both figures include $284 million of acquired IPR&D, upfront and milestone expense, which the company attributed mainly to the acquisition of RayThera Inc.

3. 03

   The company said net cash flow from operations for Q3 2026 was approximately $641 million, capital expenditures were approximately $40 million, and free cash flow was approximately $600 million. As of September 30, 2026, cash and cash equivalents were approximately $1.3 billion, total debt was approximately $7.7 billion, and net debt was approximately $6.4 billion.

4. 04

   The company said it raised the lower end of its full-year 2026 Non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00. It cited ongoing business strength and Apellis dilution as reasons for the change.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.